UnitedHealth vs. Cigna: Which Insurer to Buy Amid Sector Turmoil?

Amid significant healthcare sector turmoil characterized by surging medical costs and regulatory headwinds, UnitedHealth (UNH) withdrew its 2025 guidance and missed Q1 estimates, leading to a 40.8% year-to-date share decline due to unexpected utilization and DOJ scrutiny. Conversely, Cigna (CI) raised its full-year adjusted EPS guidance to at least $29.60, benefiting from strategic divestments of government-backed businesses and a robust commercial-heavy model, resulting in an 11.8% YTD stock increase. This divergence, coupled with Cigna's lower valuation (9.82x forward P/E vs. UNH's 12.67x), positions CI as a more resilient and attractive investment with a clearer earnings outlook and a more dependable risk-adjusted profile amidst ongoing sector volatility.

Analysis

The U.S. managed care sector is experiencing significant disruption from surging medical costs and regulatory pressure, creating a clear divergence in performance between UnitedHealth (UNH) and Cigna (CI). UnitedHealth is facing considerable headwinds, evidenced by its withdrawal of 2025 guidance, a Q1 2025 earnings and revenue miss, and a 40.8% year-to-date decline in its share price. These challenges are compounded by regulatory scrutiny, including DOJ inquiries and pressure on its Optum Rx PBM, as well as an unexpected CEO transition. While UNH maintains formidable scale and generated strong operating cash flows of $5.5 billion in Q1, the Zacks Consensus Estimate for a 21% EPS decline in 2025 underscores the prevailing uncertainty. In stark contrast, Cigna has strategically de-risked its profile by divesting its Medicare Advantage and other government-related businesses, focusing on a more stable commercial-heavy model. This pivot is yielding positive results, with Cigna raising its full-year adjusted EPS guidance to at least $29.60 and its stock gaining 11.8% YTD. Cigna's favorable valuation, trading at a 9.82x forward P/E compared to UNH's 12.67x, and a lower long-term debt-to-capital ratio of 39.56% further enhance its appeal as a more resilient investment with a clearer earnings trajectory.

Key Decisions for Investors

• Investors should consider Cigna's strategic shift to a commercial-focused model and its raised EPS guidance as strong positive signals, suggesting it is better positioned to navigate the current sector-wide volatility.
• Exercise caution with UnitedHealth, as its withdrawn 2025 guidance, ongoing regulatory investigations, and significant stock underperformance indicate substantial near-term risks that may not be fully compensated by its scale and cash flow generation.
• Given Cigna's lower forward P/E of 9.82x compared to UnitedHealth's 12.67x and its clearer earnings outlook, a relative value or pair trade strategy favoring a long position in CI against an underweight or short position in UNH could be an effective approach.
• Monitor any updates from UnitedHealth regarding its 2025 earnings outlook and the resolution of regulatory inquiries, as these will be critical catalysts for a potential re-rating of the stock.